SalubrisBio
11
15M
9
0.42
5
0.18
1
- Areas of investment
Summary
In 1998 was created SalubrisBio, which is appeared as Corporate Investor. The company was established in Asia in China. The leading representative office of defined Corporate Investor is situated in the Shenzhen.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2018. The fund is generally included in less than 2 deals every year. The real fund results show that this Corporate Investor is 55 percentage points more often commits exit comparing to other companies.
The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most successful fund investment fields, there are Health Care, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Viracta Therapeutics, GO Therapeutics, KingstronBio. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 1 partaker. Despite the SalubrisBio, startups are often financed by Latterell Venture Partners, Forward Ventures, Crocker Capital. In the next rounds fund is usually obtained by Taiwania Capital.
Investments analytics
Analytics
- Total investments
- 11
- Lead investments
- 5
- Exits
- 1
- Rounds per year
- 0.42
- Follow on index
- 0.18
- Investments by industry
- Pharmaceutical (7)
- Biotechnology (6)
- Health Care (6)
- Medical (4)
- Medical Device (3) Show 7 more
- Investments by region
-
- United States (6)
- China (5)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 16
- Group Appearance index
- 0.18
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| SalubrisBio | 22 Apr 2024 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 35M | United States, Maryland, Gaithersburg |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.